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Patients with drug allergy show a specific immune
response to drugs. Chemically nonreactive drugs like,
for example, local anesthetics are directly recognized
by abF T cells in an HLA-DR restricted way, as
neither drug metabolism nor protein processing is
required for T cell stimulation. In this study we
identified some of the structural requirements that
determine cross-reactivity of T cells to local
anesthetics, with the aim to improve the molecular
basis for the selection of alternatives in individuals
sensitized to a certain local anesthetic and to better
understand presentation and T cell recognition of these
drugs. Fifty-five clones (52 lidocaine specific, three
mepivacaine specific from two allergic donors) were
analyzed. Stimulatory compounds induced a down-
regulation of the T cell receptor, demonstrating that
these non-peptide antigens are recognized by the T cell
Drugs are examples of non-peptide antigens. Theimmune response to drugs has been mainly investi-gated with penicillin G, where it has been shown thatpenicillin G binds covalently to proteins resulting inaltered self structures, which are recognized by B
and T cells (hapten model). Recognition of penicillins and other
drugs by specific T cells is HLA restricted and antigen-presenting
cell (APC) dependent (Brander et al, 1995; Padovan et al, 1997;
Pichler et al, 1998).
The fine specificity of drug recognition by the immune system
has been mainly investigated with the β-lactam model comparing
different penicillins: A number of patients have been described,
who form IgE antibodies (MoAb) that can discriminate between
penicillin G, ampicillin or other semisynthetic penicillins (Blanca
et al, 1989; Miranda et al, 1996; Silviu-Dan et al, 1996). By using
β-lactam specific T cell clones (TCC) it was found, that the
antigenic epitope consisted of both the amide-linked side chain,
which is different in every member of the penicillin family, as well
as the thiazolidine ring common to all penicillin derivatives (Mauri-
Hellweg et al, 1996; Padovan et al, 1996). Earlier studies in the
mouse model with specific T cells for arsenylated ovalbumin
showed that alterations in the aromatic side chain are not recognized
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receptor itself. A consistent cross-reactivity between
lidocaine and mepivacaine was found, as all except
one lidocaine specific clone proliferated to both drugs
tested. Sixteen chemically related local anesthetics
(including ester local anesthetics, OH- and desalkylated
metabolites) were used to identify structural require-
ments for T cell recognition. Each of the four clones
examined in detail was uniquely sensitive to changes
in the structures of the local anesthetic: clone SFT24,
i.e., did not recognize any of the tested OH- or
desalkylated metabolites, while the clone OFB2 pro-
liferated to all OH-metabolites and other differently
modified molecules. The broadly reactive clone OFB2
allowed us to propose a model, suggesting that the
structure of the amine side chain of local anesthetics
is essential for recognition by the T cell receptor. Key
words: cross-reactivity/drug allergy/nonpeptide antigens/T
cell clones. J Invest Dermatol 112:197–204, 1999
by TCC specific for arsonate. Some of these analogs functioned
even as inhibitors for arsonate specific T cells (Rao et al, 1984).
The hapten model was, however, recently questioned as the only
model for drug recognition by our finding that glutaraldehyde
fixed cells can present sulfamethoxazole as well as lidocaine to
specific CD41 and CD81 αβ1 T cells (Schnyder et al, 1997;
Pichler et al, 1998; Zanni et al, 1998a, b) and that pulsing of APC
was not possible. Neither sulfamethoxazole nor lidocaine are
chemically reactive, but are nevertheless presented and recognized
by specific TCC: this indicates that some drugs like local anesthetics
(LA) do not need drug metabolism or protein processing to become
immunogenic and that not all drugs behave like classical haptens,
which gain their immunogenicity only after covalent binding
to endogenous proteins. The type of drug binding to major
histocompatibility complex (MHC)/peptide and T cell receptor
(TCR) is at present unclear, but might be similar to other
pharmacologic drug–receptor interactions or the binding and
recognition of metals like Ni-salts (Romagnoli et al, 1991).
In this study we investigated the potential of LA specific TCC
to recognize chemically similar LA. We had three aims by analyzing
the fine specificity to different LA: (i) obtaining a better understand-
ing of the molecular basis for cross-reactivity, which has clinical
implications for LA-sensitized individuals, namely an improved
choice of an alternative drug; (ii) determining the fine specificity
of TCC to a drug, which is presented in a noncovalent way;
(iii) obtaining some information about the localization or orientation
of drug binding to the MHC/peptide complex or to the TCR by
detecting structural requirements for TCR recognition, as the
lability of drug binding makes usual binding studies unfeasible.
To address these questions we tested the in vivo response of
patients by patch tests to six widely used LA and analyzed the
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cross-reactivity to different LA-specific T cell lines (TCL) and
TCC. Our data underline the lack of cross-reactivity between
ester/amide LA, but demonstrate a very high degree of cross-
reactivity between lidocaine and mepivacaine. The combined
analysis of the reactivity of the four TCC analyzed in detail revealed
a possible core structure for T cell recognition. Moreover, based
on the broad reactivity of one clone we propose a model, suggesting
that the structure of the amine side chain of local anesthetics is
essential for recognition by the TCR.
MATERIALS AND METHODS
Patients All patients tested developed contact dermatitis-like symptoms
upon topical application or subcutaneous injection of lidocaine (patients
SF and OF) or mepivacaine (patient PG) (Zanni et al, 1997). Blood was
taken, when patients had recovered from the allergic reaction and informed
consent was obtained from all subjects before performing these studies.
The HLA type of donor OF was: HLA-A2, A26(10), B7, BX, Bw6,
DRB1*1501 or 1503/X, DQA1*0102/–, DQB1*0602/–, and
DPB1*0401/–; and of patient SF: HLA-A3, A29(19), B7, BX, Bw6 and
DRB1*1501 or 1503/X (Zanni et al, 1997).
Culture media Culture media (CM) consisted of RPMI 1640 supple-
mented with 10% pooled heat-inactivated human AB serum (Swiss Red
Cross, Bern, Switzerland), 25 mM HEPES buffer, 2 mM L-glutamine,
10 mg per ml streptomycin and 100 U per ml penicillin. CM1 used to
culture TCL and TCC was enriched with 20 U per ml natural interleukin-2
(a kind gift from Dr. U. Schwule`ra, Biotest, Frankfurt/Main, Germany)
and 20 U per ml recombinant interleukin-2 (Dr. A. Cerny, Inselspital,
Switzerland). The medium for culture of Epstein–Barr virus (EBV) trans-
formed B lymphoblastoid cell lines (B-LCL) was RPMI 1640 supplemented
with 10% heat-inactivated fetal bovine serum (Gibco, Paisley, Scotland),
25 mM HEPES buffer, but no L-glutamine and no antibiotics. The EBV-B
cell lines (B-LCL) were generated as described (Brander et al, 1995).
Drugs (local anesthetics) LA have an aromatic lipophilic constituent,
which is coupled via a carbonyl to a hydrophilic tertiary amine. According
to their benzoic substitution in position 1, LA are divided into ester LA
and amide LA (for structure see Table I). Ester LA have an additional
amine substitution in position 4 of the benzene ring. While amine tails in
ester LA are linear, several amide LA compounds show cyclic amine
formation (mepivacaine, bupivacaine).
All drugs used in these experiments have been previously tested for their
inhibitory activity on the proliferative response to mitogens in nonallergic
individuals and only nontoxic concentrations of the drugs have been used
for in vitro stimulations (data not shown). Preparation of drug solutions in
CM was always done freshly just before use.
Following drugs were used: lidocaine, mepivacaine, bupivacaine, etido-
caine, prilocaine (Astra, Uppsala, Sweden), encainide (Bristol-Myers
Squibb, Princeton, NJ), butanilicaine (Hoechst-Pharma, Unterschleissheim,
Germany), procaine (Siegfried AG, Zofingen, Switzerland), oxybuprocaine
(Dolder AG, Zu¨rich, Switzerland), tetracaine (Ha¨nseler AG, Herisau,
Switzerland), and tocainide (kindly provided by U. Meyer, Biozentrum,
Basel, Switzerland). Metabolites were provided by Astra, Uppsala, Sweden:
3-OH-lidocaine, Glycinexylidide HCl (GX), Monoethylglycinexylidide
HCl (MEGX), 3-OH-bupivacaine, 4-OH-bupivacaine, 4-OH-mepiva-
caine, 2-amino-2969-butyroxylidide, 4-OH-69methylalanine, and 4-OH-
2969-dimethylalanine.
Lymphocyte transformation test (LTT) Patients with presumable
allergy to LA were tested routinely in a LTT for their reactivity to six LA
(see Table I). Peripheral blood mononuclear cells (PBMC) were obtained
after the drug allergy symptoms have subsided. Briefly, freshly isolated
PBMC (1–2 3 106 cells in 1 ml CM) from these patients were cultured
in upright 12 ml tubes (Falcon, Franklin Lakes, NJ) in the presence of
different drug concentrations. After 6 d, [3H]thymidine (0.5 mCi) was
added for 14 h, cultures were harvested and cpm were measured in a β-
counter (Packard, Canberra, Meriden, CT). Stimulation indices were
calculated as ‘‘cpm in culture with antigen per cpm in culture without
antigen’’.
Generation of TCL and TCC Freshly isolated PBMC of drug allergic
patients were stimulated with lidocaine (100 µg per ml) or mepivacaine
(100 µg per ml) in CM at a cell density of 2 3 106 per well in a 24 well
plate (Falcon). To generate TCL, CM1 was added after 7 d of culture.
After 11 d, 0.8 3 106 bulk cells were restimulated with 0.5 3 106
autologous irradiated (3000 rad) PBMC, 0.3 3 106 autologous irradiated
(6000 rad) B-LCL and the same concentration of antigen used in primary
stimulations. TCL were expanded in CM1, and restimulated every 14 d
by the above described APCs and antigen. Drug-specific T cells were
cloned by limiting dilution as described earlier (Zanni et al, 1997). Briefly,
blast cells from specific TCL were seeded at 0.3, 1, or 3 cells per well
with 25,000 allogeneic irradiated PBMC into a 96 well round bottom
plate (Falcon) plus phytohemogluttinin (0.5 µg per ml) (Bacto, Difco
Laboratories, Detroit, MI) in 150 µl per well of CM. Growing TCC were
expanded in CM1 and restimulated every 14 d with allogeneic irradiated
PBMC plus phytohemogluttinin (0.5 µg per ml).
The phenotype of TCC was identified by immunofluorescence analysis
with anti-CD4, anti-CD8, anti-CD3 and anti-TCR γδ MoAb (Becton
Dickinson, Rutherford, NJ). To critically evaluate cross-reactivity of specific
TCC, proof of clonality is essential. The four clones were analyzed and
stained with a panel of 17 defined Vβ-antibodies obtained from Immuno-
tech, SA (Marseille, France) (Vβ2, Vβ3, Vβ5.1, Vβ5.2, Vβ5.3, Vβ6, Vβ8,
Vβ11, Vβ12, Vβ13.1, Vβ13.3, Vβ14, Vβ16, Vβ17, Vβ20, Vβ21, Vβ22).
Three clones gave only a positive staining for one Vβ, namely Vβ14
(SFT24), Vβ5.1 (OFZ45), and Vβ17 (OFB2), but negative staining with
all other Vβ-specific MoAb. Clone SFM8 was negative for all tested
MoAb, indicating a TCR with a Vβ not stainable by MoAb.
Proliferation of TCL and TCC to different drugs To measure the
antigen specific proliferation of TCL and TCC, 3 3 104 cells were
incubated with the same number of autologous irradiated (3000 rad)
PBMC or 5 3 103 B-LCL (6000 rad) in the presence or absence of drugs
at indicated concentrations in 200 µl CM in a 96-well round bottom plate
(Falcon). After 48 h, [3H]thymidine (0.5 µCi) was added for 14 h, cells
were harvested on glass fiber disks and counted in a microplate β-counter
(Inotech Filter Counting System INB 384; Inotech, Dottikon, Switzerland).
Stimulation indices were calculated as described above.
TCR downregulation Three times 104 clone cells were incubated
with 5 3 104 autologous B-LCL in 200 µl RPMI 10% fetal bovine serum
medium in U bottom plates in the presence of no antigen or drugs (100 µg
per ml). The plates were centrifuged for 2 min to allow conjugate formation
and incubated for 4 h at 37°C. Cells were washed with PBS containing
1% fetal bovine serum and 0.02% NaN3 and stained with a phycoerythrin-
labeled anti-CD3 and a fluoroscein-isothiocyanate-labeled anti-CD19
MoAb to exclude B-LCL. The CD3 fluorescence was analyzed on an
EPICS profile II flow cytometer (Coulter, Hialeah, FL). APC were gated
out using both forward and side scatter (FSC/SSC) and green fluorescence.
CD3, CD19 MoAb were obtained from Dako Diagnostics (Zug, Switz-
erland).
RESULTS
Patch tests do correlate with LTT In a previous study we
characterized the T cell reactivity to LA regarding symptoms,
induction of activation parameter, TCC phenotype, cytokine
release, TCRVβ pattern and HLA restriction (Zanni et al, 1997).
Table I shows the structures of LA tested and gives a summary of
results obtained with in vivo (patch tests) and in vitro data (LTT).
All three patients showed a positive patch test and LTT to the
sensitizing drug. In addition, the two patients (SF and OF) sensitized
to lidocaine reacted to mepivacaine and patient PG, originally
showing an adverse reaction to mepivacaine cross-reacted to
lidocaine. Interestingly, patients SF and OF revealed a positive skin
test and LTT to mepivacaine, although they never have received
mepivacaine treatment before. Except for patient SF, which showed
a weakly positive skin test, the patients did not react to the third
tested amide LA (bupivacaine). In general, we found a good
correlation of patch test results with the LTT. The only exception
was a negative skin test with oxybuprocaine but a weakly positive
LTT to this compound for patient SF. Only a narrow range of
concentrations resulted in a positive LTT. Concentrations between
10 and 100 µg per ml were found to be optimal for T cell
stimulation. Higher concentrations (500 µg per ml) were already
toxic and those lower (1 µg per ml) were nonstimulatory. All
results were reproducible over the tested time period of 2 y.
Local anesthetics can induce a specific TCR downregulation
There is only indirect evidence that drug recognition is TCR
mediated, as up to now no drug-specific hybridoma or TCR-
transfected cell line exists. As shown in Fig 1 the lidocaine-specific
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Table I. Chemical structures of LA and in vivo (patch test) and in vitro (LTT) tests
Patient:a OF SF PG
Sensitized to: lidocaine lidocaine mepivacaine
sex/year: f/1994 f/1992 f/1995
Drug tested Skin testsb LTTc Skin tests LTT Skin tests LTT
lidocaine pos 15 pos 18.2 pos 24.9
mepivacaine pos 9.2 pos 6 pos 26.3
bupivacaine neg 0.2 posd 0.2 neg 5.5
procaine neg 0.7 neg 1,4 neg 1.1
oxybuprocaine neg 0.7 neg 3.5 neg 0.7
tetracaine neg 1.1 neg 1.4 neg 2.4
a Results from patients tested by lymphocyte transformation test (LTT) and patch test to the relevant LA (lidocaine and mepivacaine) and to a panel of related LA are
summarized and correlated to the chemical structure of LA (13).
b Patch tests were evaluated with a 5% drug solution in PBS 24, 48, and 72 h after exposure to the allergen. Nonallergic control individuals did not show positive reactions
in the patch test or LTT (n 5 5).
c Results from LTT are given as stimulation indices (cpm in culture with antigen divided by cpm in culture without antigen). All compounds were tested with different
concentrations (1–500 µg per ml); only the concentration with maximal stimulation (100 µg) is shown. Bold numbers show elevated specific stimulation indices (stimulation
index . 3).
d Only a weak reaction after 72 h visible.
TCC OFB2 exhibits a TCR downregulation when incubated with
stimulatory drugs such as lidocaine or mepivacaine, but not when
stimulated with nonproliferation-inducing compounds, such as
MEGX or butanilicaine. The response is clearly APC dependent,
as absence of APC failed to induce a TCR downregulation
(Fig 1B). These results demonstrate that drug recognition by T
cells is associated with a downregulation of the TCR itself.
Cross-reactivity of lidocaine and mepivacaine specific TCL
It is generally assumed, that there is no immunologic cross-reactivity
between amide and ester type LA, but a detailed analysis of the
in vivo and in vitro T cell cross-reactivity has not yet been described
(Curley et al, 1986; van de Hove et al, 1994; Bircher et al, 1996).
To analyze further the in vitro cross-reactivity, we established LA-
specific TCL. In spite of several in vitro restimulations, we never
succeeded to establish TCL specific to ester LA from the originally
amide LA-sensitized donors. Additionally, it was not possible to
generate bupivacaine-specific TCL albeit this drug differs from
mepivacaine only by showing a N-butyl-piperidine instead of N-
methyl-piperidine substituent. With the help of lidocaine and
mepivacaine specific TCL from donors SF, OF and PG, we found
that these lines are cross-reactive, but do not recognize the third
tested amide LA, bupivacaine (see Table II, for chemical structures
Table I). As expected from skin test results and LTT, none of the
six established lines reacted to any of the analyzed LA of the
ester type.
Lidocaine and mepivacaine specific TCC are highly cross-
reactive to each other To see whether patients with positive
patch tests to lidocaine and mepivacaine do also show a cross-
reactivity on a clonal level, lidocaine-specific and mepivacaine-
specific TCC of two patients were generated. As shown in Table III
for patient SF, all clones specific for lidocaine are cross-reactive to
mepivacaine and, vice versa, the three tested mepivacaine-specific
clones recognized lidocaine. The possibility of analyzing sister
clones, could be ruled out as flow cytometry and polymerase chain
reaction analysis performed with seven selected clones revealed
different TCRVβ expression (data not shown). Additionally, the
cross-reactive clones showed a distinct CD41 or CD81 phenotype.
The two clones from patient OF were obtained at different time
points. They demonstrate that lidocaine-specific cells exist, which
do not recognize mepivacaine, as one clone reacted exclusively to
lidocaine.
Fine specificity of lidocaine- and mepivacaine-specific TCC
To better characterize the core structure for T cell recognition, LA
specific clones were analyzed with different, structurally slightly
modified LA and their metabolites (Tables IV–VII). All compounds
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Table II. Cross-reactivity of lidocaine- and mepivacaine-specific TCLa
Restimulation (antigen)
No antigen T cell lines Lidocaine Mepivacaine Bupivacaine Procaine Oxybuprocaine Tetracaine
Patient (cpm) generated by (SI)b (SI) (SI) (SI) (SI) (SI)
OF 42 lidocaine 156 165.4 0.9 1.2 0.9 2
22 mepivacaine 90.1 157.2 1.8 1.7 1.5 3
SF 676 lidocaine 4.8 4.8 0.7 1 0.9 0.8
207 mepivacaine 51.1 54.1 4.5 0.9 2.5 1.5
PG 2051 lidocaine 3.9 2.8 0.5 1.1 0.6 0.6
560 mepivacaine 4.2 4.4 0.6 1.5 0.8 0.9
a TCL were analyzed for cross-reactivity with three amide LA and three ester LA (chemical structure see Table I). Only lidocaine and mepivacaine revealed a positive
proliferation with a maximal response when 100 µg drug per ml where used. Results are shown for drug concentrations which yielded maximum proliferation. Results of
one of three experiments are shown.
b SI, stimulation index.
Figure 1. Local anesthetics induce a specific TCR downregulation.
Clone cells and B-LCL were mixed at a 1:2 ratio in the presence or
absence of indicated drugs (100 µg per ml) (A). (B) Various amounts of
APC were used to study the APC dependency of the response. After 4 h
cells were washed with PBS containing 1% fetal bovine serum and 0.02%
NaN3 and stained with a phycoerythrin-labeled anti-CD3 and a fluoroscein-
isothiocyanate-labeled anti-CD19 or anti-CD20 MoAb to exclude B-LCL.
The CD3 fluorescence was analyzed on an EPICS profile II flow cytometer.
are in clinical use, or are in vivo formed metabolites. Three clones
generated with lidocaine (SFT24 from donor SF, and OFB2,
OFZ45 from donor OF) and one clone generated with mepivacaine
(SFM8 from donor SF) were analyzed in detail. Clone OFB2 and
OFZ45 as well as SFM8 were HLA-DRB1*15 restricted as
evaluated by blocking experiments with anti-DR-antibodies and
use of HLA-DR matched allogeneic APC (Zanni et al, 1997);
clone SFT24 was HLA-DR restricted, but able to recognize
lidocaine with certain allogeneic APC as well (Zanni et al, 1998a).
Table III. Lidocaine- and mepivacaine-specific TCC cross-
react to each othera
Lidocaine Mepivacaine
Drugb Patient Phenotype specificc specific
lidocaine SF CD4 43 43
CD8 5 5
γδ 2 2
OF CD4 2 1
mepivacaine SF CD4 3 3
a Lidocaine-specific TCC of donor OF and SF were tested for recognition of
mepivacaine and mepivacaine-specific clones obtained from donor SF were analyzed
for lidocaine specificity. A positive reaction was determined as an stimulation index
. 3 for both drugs.
b Clone generated with drug indicated.
c Number of clones with a stimulation index .3.
Binding of drugs to the MHC–peptide complex To predict a possible
TCR contact site of a drug it is essential to know that all tested
compounds bind to the MHC–peptide complex. Of 16 compounds
tested (see below) nine were stimulatory at least for one of the
four clones tested, which implies presentation of these compounds.
We cannot determine with security, whether the nonstimulatory
compounds bind to HLA-DR molecules, as the unstable binding
of drugs to the MHC–peptide complex (removed by washing)
makes binding studies not feasible. As the fine specificity of the
TCR (see below) seem to be directed to the amine side chain, we
believe that the benzene ring is important for presentation. As
nonstimulatory compounds have the same benzene substitutions
like lidocaine we assume that in principle all tested compounds are
able to bind.
Lidocaine-specific TCC do not recognize ester LA As expected from
the data obtained with patch tests, LTT and TCL, lidocaine-specific
and mepivacaine-specific TCC do not cross-react with ester LA.
Proliferation assays with procaine, oxybuprocaine or tetracaine
never resulted in a positive proliferation for all four clones tested
(data not shown).
Formation of cyclic amine and OH-metabolites can be tolerated The
most widely used LA besides lidocaine are mepivacaine and
bupivacaine, which have an intramolecular amine (piperidine-ring)
instead of a linear diethylamine structure. As results with skin tests,
LTT and TCL revealed cross-reactivities to mepivacaine, we
included OH-metabolites (OH residues in positions 3 and 4 of the
benzene; numbering see Table IV) in our experiments. As shown
in Table IV, the four clones tested revealed a different pattern of
cross-reactivity: Clone SFT24 tolerated the piperidine residue if
substituted with a methyl (mepivacaine), but not with a butyl
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Table IV. Cross-reactivity of LA-specific TCC to LA bearing cyclic amines and their OH-metabolitesa
No antigen Lidocaine 3-OH-lidocaine Mepivacaine 4-OH-mepivacaine Bupivacaine 3-OH-bupivacaine 4-OH-bupivacaine
Clone (cpm) (SI) (SI) (SI) (SI) (SI) (SI) (SI)
SFT24 631 13.4 1.0 16.4 0.8 1.8 0.7 0.6
OFZ45 612 17.3 14.4 1.6 1.1 6.9 6.9 1.2
SFM8 160 91.4 20.8 51.6 6.7 2.7 11.0 2.1
OFB2 623 9.8 10.0 20.0 11.6 15.9 11.8 8.7
a Lidocaine- and mepivacaine-specific TCC do cross-react to compounds containing N-methyl-piperidine (mepivacaine) (clone SFT24 and SFM8), to N-butyl-piperidine
(bupivacaine) (clone OFZ45) exclusively or tolerate both amine modifications (clone OFB12). OH-metabolites are not recognized by clone SFT24. Clone OFZ45 and SFM8
reacted with metabolites containing a hydroxylation in position 3, while clone OFB2 proliferates to both 3-OH and 4-OH metabolites. All compounds were tested with
different concentrations (1–500 µg per ml). Only the highest values of proliferation are shown (100 µg per ml). One of three representative experiments is shown.
Table V. Cross-reactivity of LA-specific TCC to LA
bearing primary amine side chainsa
No antigen Lidocaine Butanilicaineb MEGX GX
Clone (cpm) (SI) (SI) (SI) (SI)
SFT24 631 13.8 0.8 0.9 0.9
OFZ45 390 31.0 1.2 1.5 1.6
SFM8 56 32.6 0.5 2.2 2.4
OFB2 1423 7.0 0.7 0.2 0.3
a LA-specific TCC react to tertiary amines, but not to primary amines. The major
in vivo-metabolites MEGX and GX are not recognized. All compounds were tested
with different concentrations (1–500 µg per ml). Only the highest values of
proliferation are shown (100 µg per ml). One of three representative experiments
is shown.
b Butanilicaine bears a chloride instead of a methyl in position 2 of the benzene ring.
group (bupivacaine). No reaction is seen to any of the hydroxylated
metabolites. The recognition of clone OFZ45 is different: As in
the case of clone SFT24, the cyclic amine is tolerated, but in
contrast to clone SFT24, only in the case of a butyl but not a
methyl substitution. A reaction to OH-metabolites was limited to
compounds hydroxylated in position 3, namely 3-OH-lidocaine
and 3-OH-bupivacaine, but not to 4-OH-metabolites. The mepiva-
caine-specific clone SFM8 cross-reacted to lidocaine and also
recognized 3-OH-metabolites. In addition, a weak response to 4-
OH-mepivacaine was detected. Clone OFB2 showed the widest
cross-reactivity, as it reacted independently of the N-substitution
to both compounds bearing piperidine-residues and recognized 3-
OH- as well as 4-OH-metabolites.
Single de-ethylation of the tertiary amine is not tolerated The first
in vivo metabolism of most amide LA occurs via N-de-ethylation
and results in monoethylated (MEGX) and the diethylated (GX)
metabolites. As studies with sulfamethoxazole proposed a T cell
reactivity not to the drug itself, but to its hydroxylamine metabolite,
which can be formed from primary amines, we wondered whether
we could detect a cross-reactivity to primary or secondary amines
of lidocaine (Rieder et al, 1989; Cribb et al, 1991). Such a reactivity
would be expected if drug metabolism is required for T cell
recognition. As shown in Table V, in the absence of one or both
N-alkyl substituents, resulting in primary or secondary amine
structures, no T cell response is detectable, falsifying the hypothesis
of drug metabolite recognition.
Modification of the linear amine structure can be tolerated, when the α-C
is alkylated Drugs like prilocaine, tocainide, or etidocaine reveal
an additional alkylation (methyl or ethyl) of the α-C to the
carbonyl. Interestingly, clone OFB2, which recognized already all
the compounds bearing cyclic amine, showed a cross-reactivity to
etidocaine and prilocaine, both of which display an α-ethyl
substitution and a N-alkylation (see Table VI). No reactivity is
seen with α-C alkylation in the absence of N-alkylation (2-amino-
2969-butyroxilidide, tocainide).
Cleavage products are not recognized Another example of in vivo
lidocaine metabolites are 4-OH-2969-dimethylaniline or 4-OH-
69-methylaniline. These structures were not recognized by the
tested lidocaine-specific TCC (see Table VII).
DISCUSSION
In this study we used T cells from lidocaine- or mepivacaine-
sensitized individuals to analyze the fine specificity of drug recogni-
tion by αβ1 TCR. The data obtained have implications for the
clinical situation, namely the choice of an appropriate LA in already
sensitized patients. Moreover, they give insight and illustrate the
high degree of specificity of the TCR reacting with small molecular
compounds, such as drugs, and may help to understand better how
drugs are recognized by T cells.
Our data confirmed previous studies that ester and amide LA
do not cross-react in vivo and in vitro (Curley et al, 1986; van de
Hove et al, 1994; Bircher et al, 1996). Until now, analysis of allergic
cross-reactivities within the amide LA group have been limited to
patch tests and LTT in selected case reports (Curley et al, 1986;
van de Hove et al, 1994; Bircher et al, 1996). Here we could show
a high degree of cross-reactivity between lidocaine and mepivacaine
also on the clonal level. Mepivacaine elicits a T cell reaction in
the two patients originally sensitized to lidocaine and patient
PG, originally sensitized to mepivacaine, showed a similar strong
response to lidocaine as to mepivacaine. As we observed a very
good agreement between clinical sensitization, patch and LTT, we
believe it to be justified to recommend that lidocaine-sensitized
patients should not be treated with mepivacaine (and vice versa).
A second aspect of this study is a better understanding how T
cells recognize drugs, and how small modifications of the sensitizing
molecule may affect T cell stimulation. The four clones analyzed
202 ZANNI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Table VI. Cross-reactivity of LA-specific TCC to LA bearing a a-C-alkylation and a modification of the linear aminea
2-Amino-2969-
No antigen Lidocaine Tocainide Prilocaine butyroxylidide Etidocaine
Clone (cpm) (SI) (SI) (SI) (SI) (SI)
SFT24 117 128.2 0.8 1.0 4.6 4.3
OFZ45 390 31.0 0.9 1.4 1.2 1.3
SFM8 56 32.6 0.8 1.0 3.1 1.4
OFB2 1423 7.0 0.9 4.5 1.3 6.0
a Clones SFT24, OFZ45 and SFM8 do not react to compounds bearing α-C alkylations. In contrast, clone OFB12 recognizes structures with α-C alkylations, but only in
association of a secondary or tertiary but not a primary amine. All compounds were tested with different concentrations (1–500 µg per ml). Positive stimulations were found
with 100 µg per ml. One of three representative experiments is shown.
Table VII. Cross-reactivity of LA-specific TCC to cleavage
productsa
4-OH-2969 4-OH-69-
No antigen Lidocaine dimethylalanine methylalanine
Clone (cpm) (SI) (SI) (SI)
SFT24 631 13.4 0.4 0.6
OFZ45 612 17.3 1.0 0.4
SFM8 56 32.6 2.4 1.7
OFB2 623 9.8 0.3 0.4
a During metabolism, the acid amine bridge in lidocaine can be cleaved to 4-OH-
methylamine derivatives. Both resulting products namely 4-OH-2969-dimethylalanine
and 4-OH-69-methylamine are not recognized, however. All compounds were tested
with different concentrations (1–500 µg per ml). Positive stimulations were found
with 100 µg per ml. One of three representative experiments is shown.
in detail revealed a unique pattern of T cell recognition: one clone
(SFT24) did only recognize lidocaine and mepivacaine, but no
OH-metabolites. Clones OFZ45 and SFM8 exclusively reacted to
3-OH-metabolites and tolerated only certain cyclic amine residues.
The broadly reactive clone OFB2 tolerated OH-substitutions on
the benzene ring at position 3 or 4, reacted to linear and cyclic
amines, and recognized secondary amines if the molecule has an
α-C alkylation.
The different ability of cross-recognition is not due to a different
MHC restriction of the clones: both clones of donor OF were
HLA-DRB1*15 restricted (Zanni et al, 1997), but showed either
a rather narrow (OFZ45) or broad (OFB2) cross-reactivity pattern.
Hydroxylation of the benzene ring did thus not affect the ability
to be presented by the HLA-DR molecule. The TCC of donor
SF (SFM8 and SFT24) were also HLA-DRB1*15 restricted. Clone
SFT24 was, however, peculiar, as it was able to recognize lidocaine
not only with the autologous DRB1*15, but also with different
HLA alleles (Zanni et al, 1998a). This peculiar (‘‘promiscuous’’)
presentation of lidocaine by different HLA-DR molecules to the
clone SFT24 illustrates that different HLA-DR molecules have the
possibility to present lidocaine (Zanni et al, 1998a).
The different stimulatory capacity of structurally related com-
pounds suggest, that certain residues of the lidocaine molecule are
more important for TCR recognition and subsequent proliferation
than others (Fig 2A). As ester LA are not recognized by the TCC
tested, the amide coupled to the benzene ring could be one of the
core residues recognized by the TCR. Because all clones are able
to respond to certain cyclic amines, we assume that the amine side
chain is another residue pointing to the TCR. Clone OFB2 allows
us to speculate how alterations in the chemical structure of the
amine side chain has consequences for T cell recognition: As
outlined in Fig 2(A), all compounds recognized by clone OFB2
bear a side chain either in the form of a tertiary amine (diethylamine
or a piperidine) or a secondary amine with an alkylation of the
α-C to the carbonyl group (prilocaine, etidocaine). This suggests
that two contact residues within the amine side chain are required
to interact with the TCR to induce T cell proliferation. Compounds
with only one residue (primary amines) are not capable to induce
cell proliferation (Fig 2B).
There are at least two ways how drugs are presented by the
MHC–peptide complex to T cells. Per se reactive haptens such
as penicillin G are assumed to be covalently bound to the
peptide presented by the MHC molecule (Brander et al, 1995;
Padovan et al, 1997). For per se nonreactive drugs, such as
sulfamethoxazole or lidocaine, we recently demonstrated a direct,
noncovalent interaction with the MHC–peptide complex, not
requiring processing or drug metabolism (Schnyder et al, 1997;
Pichler et al, 1998; Zanni et al, 1998a, b). The failure of
lidocaine metabolites to stimulate LA-specific TCC further
supports this concept.
As this direct drug binding is labile, it is difficult to investigate
where the drug binds exactly; in particular, whether the drug is
presented by binding to the peptide or the MHC molecule itself
(or both). The site of TCR engagement is also still unclear. Here
we show a direct involvement of the TCR itself in the recognition
of drugs. This rules out a TCR-independent stimulation of T cells
as shown recently for tucaresol. This aldehyde drug binds covalently
via Schiff-bases to T cell surface amines (on CD2 molecules) and
stimulates T cells by evoking a co-stimulatory signal (Rhodes
et al, 1995). Further, indirect evidence suggest that drugs bind
preferentially to the Vβ chain of the TCR, as we found repeatedly
an expansion of certain TCR Vβ chains when PBMC were
stimulated with drugs, such as sulfamethoxazole, penicillin G or
lidocaine (Mauri-Hellweg et al, 1995, 1996; Zanni et al, 1997).
The labile, simultaneous interaction of drugs with these two
‘‘immunologic’’ relevant receptors, namely the TCR and the
MHC–peptide complex is rather similar to the interaction of drugs
to ‘‘pharmacologic’’ receptors such as benzodiazepine or opoid
receptors: It is reversible, dose and configuration dependent. A
major difference is, however, the need of an appropriate APC to
present the drug. This requirement of dual interaction, namely to
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Figure 2. Possible core structure of T cell recognition by lidocaine-
specific TCC OFB2. (A) Based on the data obtained with various
compounds bearing different amine side chain residues a model of T cell
recognition of the rather broadly reactive clone OFB2 can be outlined.
Side chains recognized (1) or not recognized (–) are listed according to
the data shown in Tables IV–VII. All compounds with a tertiary amine
(linear or cyclic) are recognized by clone OFB2. In contrast, primary
amines never elicited a T cell response. Secondary amines can be recognized,
but only if the compound bears an additional α-C-alkylation in the
structure. (B) Simplified scheme postulating that the TCR of clone OFB2
transmits a proliferative signal only if two rather bulky substituents of the
amine side chain are interacting.
the TCR and the MHC–peptide complex, might be the reason
for the narrow dose–response curve frequently observed in drug-
specific T cell stimulations (Nyfeler and Pichler, 1997). Moreover,
it could explain why already minor modifications in the chemical
structure of a drug abrogate its ability to elicit a T cell proliferation,
while a ‘‘pharmacologic’’ receptor is frequently triggered by com-
pounds, which can differ in their chemical structure substantially.
In pharmacotherapy several drugs can act as partial agonists or
antagonists for their receptors (Akil et al, 1976; Mohler and
Richards, 1981). Similarly, small modifications in the immunogenic
peptide can drastically alter TCR signaling and T cell function
(Evavold and Allen, 1991; Sloan-Lancaster et al, 1993, 1996). In
analogy to this, small modifications of a drug able to interact with
the TCR might also alter TCR signaling. Indeed, a recent study
using peptides covalently modified with the hapten trinitrophenol
revealed that specific TCC could be antagonized by ligands altered
in their hapten structure (Preckel et al, 1997). Further work will
show, whether ‘‘altered drug ligands,’’ able to interact directly
with the MHC–peptide complex and TCR, may exert a similar
modifying effect on T cell functions.
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